multicenter, USA - 19 Mar `18Aclaris Therapeutics: Topical Solution

Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo

In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages eligible: 18 Years to 65 Years

Locations: Aclaris Investigator Site 

  • Encinitas, California, United States, 92024
  • Los Angeles, California, United States, 90036
  • Worcester, Massachusetts, United States, 01655
  • Dallas, Texas, United States, 75390
  • Lynchburg, Virginia, United States, 24501

Status: Unknown, not recruiting

Start date: March 19, 2018
Completion date: September 30, 2019

Identifier: ClinicalTrials.gov NCT03468855

Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.

FAQOther Questions

  • How can I explain vitiligo to my children?

    Vitiligo can be puzzling for a child because a person who has it isn't "ill" in a common sense.  To choose the right words to explain vitiligo diagnosis to a child, first consi...

  • What causes vitiligo?

    Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...

  • What is the best therapy for localized vitiligo?

    An investigation from Egypt cites early systemic immunomodulation for recent localized vitiligo as a “successful approach” for achieving early control of disease activity. It he...